A Study for Aggressive Adult T-cell Leukemia-lymphoma (ATLL)
To test the superiority of VCAP-AMP-VECP regimen over biweekly-CHOP in aggressive ATLL in terms of survival benefit.
Adult T-cell Leukemia|Lymphoma
DRUG: VCAP-AMP-VECP with G-CSF and intrathecal prophylaxis|DRUG: biweekly-CHOP with G-CSF and intrathecal prophylaxis
Overall survival
Toxicity|CR rate|Progression free survival
Nothing to describe.